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There are opportunities to formulate antibodies as solid-state depots for local therapy, which 
would minimise large systemic doses that are typically required. We have developed antibody 
mimetics known as Fab-PEG-Fab (FpF) that display similar binding affinity and functional 
activity as IgG antibodies. For head-to-head comparison between FpF and IgG, FpF is prepared 
from the Fabs obtained by enzymatic digestion of IgGs.  Here, we report for the first time that 
using different enzymes to proteolytically digest IgG plays an important role in stability profile 
of the obtained Fabs leading in different stability profiles of the final conjugated product such 
as FpF.  We prepared an anti-vascular endothelial growth factor (VEGF) FpF from either 
clinical Fabrani (ranibizumab) or Fabs obtained by enzymatic digestion of bevacizumab (IgG) 
using immobilised papain and gingisKHANTM (KGP) enzyme. The stability of FpFs was then 
studied after being lyophilised in comparison with both ranibizumab and bevacizumab.  
Lyophilisation is being evaluated to produce solid material that can be used for depot 
fabrication.  We observed that using immobilised papain to digest IgG resulted in the 
heterogenous isomers Fab leading to the preparation of heterogenous FpFbeva-papain mimetic 
that underwent aggregation during lyophilisation.  However, using KGP enzyme generated a 
homogenous intact Fabbeva-KGP as determined by mass spectral analysis. Interestingly, the FpF 
mimetics prepared from the homogenous Fabs (Fabrani and Fabbeva-KGP), displayed greater 
stability compared to their starting bevacizumab and ranibizumab after being lyophilised as 
determined by DLS analysis. There is a potential to lypholise FpFs to be used to fabricate solid-






We have developed an antibody mimetic called Fab-PEG-Fab (FpF) (Fig. 1a) [1], which displays 
similar in-vitro and in-vivo activities as the corresponding IgG that binds to the same epitope 
[2]. The two Fabs in an IgG antibody are linked together through the flexible hinge region to 
(i) facilitate Fab binding to two epitopes spanning a wide spatial range [3] and (ii) allow 
cooperative binding of the two Fabs.  However, the hinge region in IgG is vulnerable to 
degradation [4] and disulfide scrambling [5].  In antibody mimetic, FpF, the hinge region is 
replaced with poly(ethylene glycol) (PEG) scaffold. The resulting FpF does not possess a Fc 
region and also avoids Fc effector derived side effects [8, 9], which are particularly important 
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when considering treatments for acute inflammatory conditions. The Fab interchain disulfides 
in the FpF mimetics, are also stabilised by reannealing disulfide bridging conjugation. Disulfide 
reannealing conjugation and the presence of PEG reduces the propensity of the FpFs to 
aggregate. Binding affinity properties are enhanced because the flexibility of the PEG slows 
dissociation of the FpF from its antigenic site resulting in the potential to increase duration of 
action within the target tissue.  
We have recently prepared a solid-state bevacizumab tablet for intraocular 
implantation [6]. Bevacizumab is an humanized IgG that binds to vascular endothelial growth 
factor (VEGF) and used in oncology and age macular degeneration (AMD) [7]. Bevacizumab 
has shown the potential to control scarring when administered into the subconjunctiva 
following glaucoma filtration surgery (GFS) but clears quickly after subconjunctival injection. 
There is a need for a slow releasing form of an anti-VEGF antibody solid-state depot that can 
be placed in the subconjunctiva space of the eye after surgery and maintained its stability 
during long period of time.  We hence wished to study the stability of anti-VEGF FpF mimetic 
after lyophilisation. if it remains stable, it might then be possible to formulate high enough 
amount of mimetic as a solid-state tablet to display prolonged duration of action. 
Lyophilisation (freeze-drying) is one of the well-known method to formulate proteins as a 
solid-state depot.  
Figure (1)  
 
The Fab used to prepare an FpF can be derived directly by the enzymatic digestion of 
bevacizumab (Fig. 1b) or use a clinical Fabrani (ranibizumab, an anti-VEGF Fab). We first 
prepared the FpFrani from Fabrani [1] and studied its stability by dynamic light scattering (DLS) 
and size-exclusion chromatography (SEC) after being lyophilised. While lyophilised FpFrani 
maintained its stability, the lyophilised Fabrani in its pharmaceutical formulation 
aggregated/degradated. We then wanted to expand our study to determine stability of 
lyophilised FpF prepared from bevacizumab. To prepare intact Fabbeva with one interchain 
disulfide bond, we used two enzymes; papain and gingisKHANTM. Both enzymes efficiently 
produced Fabs without impacting the integrity of the binding site [10].  Papain is the most 
common proteolytic enzyme that is used widely, but this enzyme cleaves the IgG hinge region 
at various sites resulting in a heterogenous Fabs possessing varying residual hinge derived 
polypeptide still bond to the Fab. We and others [10] have shown the heterogenicity of a 
papain digested Fab by mass spectroscopy. However, there has not been any study to 
investigate stability of the Fab obtained by papain digestion and its impact on stability of the 
conjugated products. There are wide range of applications where Fabs are used for protein 
conjugations such as antibody drug conjugates, bispecific antibodies and radiolabel antibody 
fragments [11, 12].    
In contrast, a relatively new enzyme called gingisKHAN (KGP) undergoes selective IgG 
hinge cleavage at a single digestion site resulting in an homogenous intact Fabs (FabKGP). We 
aimed to determine if FpFs prepared from Fabs obtained from papain and KGP (FpFbeva-papain 
or FpF beva-KGP) digestion of the IgG, displayed a different stability profile and whether they 
were more stable than the IgG during freeze-drying. We have learned that while Fabs 
obtained from bevacizumab digested by papain and KGP resulted in a single 50 kDa band in 
SDS-PAGE analysis, but they appeared to have different LC-MS peaks. In this study, we have 
noted that using homogenous, intact Fabbeva-KGP to prepare FpF conjugates, stability of the 
FpF maintained during lyophilisation in contrast to bevacizumab which underwent 
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aggregation and light and heavy chain dissociation after lyophilisation. Hence there is a 
potential to formulate high amount of FpF as a solid-state depot for ocular application.  
 
 
Materials and Methods 
Bevacizumab (Avastin, 25 mg/mL, Genentech) was purchased commercially. Immobilized 
50% papain slurry (4.0 mL) was purchased from Thermo Fisher. GingisKHANTM (KGP) (10000 
unit, for 10 mg IgG) was purchased from Genovis.  
Bevacizumab (10 mg, 1.0 mL) was incubated with immbilised papain (400 uL, at 370C 
pH 7.4 for 7 h) or with gingisKHANTM enzyme (10000 unit, at 370C pH 8 for 1 h) to obtain Fab. 
Fabs were purified from undigested IgGs and Fc fragments using a protein A column and then 
characterised using SDS-PAGE analysis, and LC-MS.  Anti-VEGF FpFs were then prepared from 
Fabrani, FpFbeva-papain or FpFbeva-KGP (Figure 1) following the method described in [1]. 
Ranibizumab, bevacizumab, FpFrani, FpFbeva-papain and FpF beva-KGP were then subjected to freeze-
drying. Primary drying was performed at -20 0C for 12 hours at 100 μBar, followed by 
secondary drying at 20 0C for 2 hours. Aggregation/stability of both FpFbeva and bevacizumab 
was determined using a dynamic light scattering (DLS) DynoPro plate reader II and SEC. 
Surface Plasmon Resonance (SPR) technique was used to study the binding affinity of 
antibody mimetics against VEGF. The CM5 chip was functionalised with VEGF (high RU 1000) 
to study the binding activity of Fabs and FpFs.  
 
Results and Discussion 
FpFrani was prepared by bis-alkylation conjugation of anti-VEGF Fabrani (1.0 eq, 1.0 mg/mL) 
with PEG di(bis-sulfone) reagent 1 (1.0 eq, 10 kDa) [1]. FpFrani was then purified and subjected 
to freeze-drying in PBS only buffer. Purified FpFrani (before and after lyophilisation) displayed 
a single band at about 120 kDa molecular weight in SDS-PAGE analysis (Fig. 2a, lanes 1 and 2) 
indicating no protein degradation occurred during lyophilisation.  Dynamic light scattering 
(DLS) analysis indicated that FpFrani maintained its stability after lyophilisation (Fig. 2b) while 
lyophilised Fabrani aggregated (Fig. 2c). In addition, there was no HMW peak in the SEC of 
FpFrani (Fig. 2d), whereas lyophilised Fabrani displayed a high molecular weight (HMW) peak at 
11.05 min consistent with aggregation having occurred. 
 
(Figure 2) 
It was important to study the binding of lyophilised FpF mimetic and whether its antigen 
binding activity is preserved. It appeared that the FpFrani maintained its binding activity to the 
VEGF after being lyophilized studied by SPR analysis (Fig. 3).    
 
(Figure 3) 
To better conduct head to head comparisons of the FpFs with IgGs, it was required to obtain 
Fab of the IgG by enzymatic digestion. We first used immobilised papain which is the most 
common enzyme for antibody digestion [1]. Using bevacizumab, Fabbeva-papain was isolated 
which was used to prepare the corresponding FpFbeva-papain with PEG di(bis-sulfone) reagent 
1. The purified FpFbeva-papain  in PBS only buffer was then subjected to freeze-drying to produce 
a lyophilised cake. Surprisingly, the FpFbeva-papain was aggregated after lyophilisation and 
multiple peaks were observed by DLS analysis (Fig. 4a). In addition, HMW and degradation 
peaks were observed by SEC for lyophilised FpFbeva-papain  (Fig. 4b). As expected, bevacizumab 
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in its pharmaceutical formulation displayed multiple DLS peaks indicating aggregation had 
occurred during lyophilisation (Fig. 4c).  
(Figure 4) 
We considered that a more selective digestion enzyme was required. Papain is a non-specific 
protease which cleaves IgG above the hinge region at the N-terminal but below the site of the 
disulfide bond between the light and the heavy chain. Because the hinge region is more 
exposed and flexible, it is more susceptible for the proteases cleavage. IgG digestion with the 
endoproteinase papain to obtain Fabs generally suffer from the presence of undigested IgG, 
over-digestion and lack of homogeneity and reproducibility. In addition, use of unspecific 
proteases required time-consuming optimizations and further purification of the Fabs to 
prevent their degradation. In addition, the integrity of interchain and intrachain disulfide 
bonds presence in Fab region, could get influenced by papain digestion. The cysteine protease 
gingipain K  [13] of the pathogenic anaerobe bacteria Porphyromonas gingivalis has recently 
become commercially available as the recombinant protease GingisKHANTM  (KGP) from 
Genovis AB (Lund, Sweden). It has been reported gingipain k could hydrolyze human IgG1 at 
a single site above the hinge region (KSCDK/THTCPPCP) generating a homogenous pool of 
intact Fabs and crystallizable fragments (Fcs). It is suggested that IgG digestion with 
GingisKHANTM is highly specific and quantitative, does not require much optimization. There 
might be a difference  
KGP enzyme was then used to digest bevacizumab to give Fabbeva-KGP.  The purified 
Fabbeva-KGP appeared at 50 kDa molecular weight band (Fig. 5, lane 1) in SDS-PAGE analysis 
similar to Fabbeva-papain (Fig. 5c, lane 2).  We learned that while both Fabbeva-papain and Fabbeva-
KGP appeared as a single band in SDS-PAGE analysis, LC-MS analysis detected 3 different 
isomers for Fabbeva-papain (Fig. 5a) and an additional peak at 23446.76 Da for a free light chain 
as a result of Fab-disulfide reduction. In contrast, Fabbeva-KGP displayed only a single LC-MS 
peak at 48381.72 Da (Fig. 5b) indicating a homogenous intact Fab.  
(Figures 5) 
FpFbeva was then prepared from Fabbeva-papain and Fabbeva-KGP. Using SDS-PAGE gel (Fig. 6, a) for 
the final purified FpFbeva-papain and FpF beva-KGP, no difference between the two FpFs could be 
discerned by SDS-PAGE in terms of the band shapes and purities. However, when the FpFbeva-
KGP was subjected to freeze-drying in PBS only buffer, interestingly, the FpFbeva-KGP did not 
aggregate or display any light/heavy chain dissociation and appeared as a single DLS peak was 
observed (Fig. 6, b).  
(Figure 6) 
 
KGP enzyme digested IgG1 between K223 and T224 to produce intact and homogenous Fab 
in less than 2 hour, leading to the preparation of homogenous antibody mimetic FpF.  Using 
papain to digest IgG could result in a combination of under- and over-digestion which 
required specific optimisation and chromatographic purification to obtain desire Fabs.  
In summary, our results suggest that FpFs are more stable than bevacizumab during 
lyophilization while maintaining the binding activity to the VEGF. We also learned that 
sourcing a pure, homogenous and intact Fab to prepare FpF could play an important rule in 
the stability of final FpF. Since FpF remains stable during lyophilization, there is a potential to 
lyophilise FpF with high loading in a solid formulation.  Highly loaded implants are desired as 
a means to further increase the duration of action of the implanted drug.   
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Figure 1. (a) Representation of the Fab-PEG-Fab (FpF) antibody mimetic and an IgG antibody, 
(b) Enzymatic digestion of IgG using either papain or ginigisKHANTM which is then followed by 










Figure 2. (a) Representative SDS-PAGE for purified FpFrani before and after lyophilisation, (b, 
c) Representative DLS analysis for Fabrani and FpFrani before and after lyophilisation. While the 
FpFrani was lyophilised in PBS buffer, the Fabrani was freeze-dried in its pharmaceutical 
formulation, (d) SEC overlays for Fabrani and FpFrani before and after lyophilisation, which 
indicate aggregation having occurred for Fabrani.  The Fabrani SECs indicate that loss of 
monomer peak at 13.8 min and presence of HMW peak at 11.05 min.   Lyophilised FpFrani 
maintained its stability studied by DLS and SEC. 
 
 
Figure 3.  Biacore SPR analysis for Fabrani and lyophilised FpFrani. CM5 chip was immobilised 








 Figure 4.  (a, b) Representative DLS and SEC analysis for FpFbeva-papain and (c) Representative 
DLS analysis for bevacizumab before and after lyophilisation. Surprisingly, FpFbeva-papain in PBS 
buffer displayed aggregation after being lyophilised as multiple peak observed in DLS. SEC 
also revealed the HMW peaks at 7.02 and 8.3 min and also degradation peak at 11.13 min for 
lyophilised FpFbeva-papain.  Bevacizumab, also displayed aggregation when lyophilised being in 




Figure 5.  (a, b) LC-MS analysis for purified (a) Fabbeva-apapain and (b) Fabbeva-KGP.  While  Fabbeva-
papain resulted in heterogenous three mass spectroscopy peaks, Fabbeva-KGP showed only one 
LC-MS peak suggesting an homogenous intact pool of Fabs. (c) Representative SDS-PAGE gel 
for purified Fabs obtained from gingisKHAN (lane 1) and papain (lane 2) digestion of 





Figure 6. (a) Representative SDS-PAGE gels for the final purified FpFbeva-papain and FpFbeva-KGP. 
Gels were stained with colloidal blue, Lane M; protein Standard, lanes 1, 2; purified FpF beva-
papain and FpFbeva-KGP respec tively appeared at about 120 kDa molecular weight band (2 x 50 
kDa Fabs + 10 kDa PEG; PEG moves twice its molecular weight size; overall is 120 kDa). (b) 
DLS analysis for FpFbeva-KGP before and after lyophilisation in PBS only buffer. FpFbeva-KGP 
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